Genomic Valley Biotech Ltd. reported unaudited standalone earnings results for the third quarter and nine months ended December 31, 2015. For the quarter, the company reported net sales/income from operations of (net of excise duty) of INR 268,000 against INR 46,800 a year ago. Loss from operations before other income, finance costs and exceptional item was INR 1,791,627.67 against INR 338,440.50 a year ago. Profit from ordinary activities before tax was INR 35,435.51 against loss of INR 24,343.85 a year ago. Net profit was INR 35,435.51 against loss of INR 24,343.85 a year ago. Basic and diluted earnings per share was INR 0.01 against INR 0.01 basic and diluted loss per share a year ago.

For the nine months, the company reported net sales/income from operations of (net of excise duty) of INR 824,540 against INR 253,330 a year ago. Loss from operations before other income, finance costs and exceptional item was INR 4,539,692.73 against INR 472,969 a year ago. Loss from ordinary activities before tax was INR 1,649,408.67 against INR 28,776.61 a year ago. Net loss was INR 1,649,408.67 against INR 28,776.61 a year ago. Basic and diluted loss per share was INR 0.54 against INR 0.01 basic and diluted loss per share a year ago.